Patents by Inventor Anne Roulston

Anne Roulston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS
    Publication number: 20210177856
    Abstract: Disclosed are methods of treating a cancer in a subject using an ATR inhibitor and PARP inhibitor. wherein the cancer has been previously identified as a cancer having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or as an ALT+ cancer. Also disclosed are methods of inducing cell death in an aberrant cancer cell having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or an ALT+ cancer cell, by contacting the cell with an effective amount of an ATR inhibitor and PARP inhibitor.
    Type: Application
    Filed: December 11, 2020
    Publication date: June 17, 2021
    Inventors: Michal ZIMMERMANN, Anne ROULSTON, Maria KOEHLER
  • Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl tranferase inhibitor
    Patent number: 8211912
    Abstract: The present invention relates to methods for decreasing cellular DNA repair in a target patient; decreasing cellular NAD+ biosynthesis in a target patient; increasing efficiency of radiation therapy in a target patient; modulating nicotinamide phosphoribosyl transferase activity in a patient; or sensitizing a patient to a DNA damaging therapy. The invention relates to methods for treating a patient who received a toxic dose of an nicotinamide phosphoribosyl transferase inhibitor. The invention also relates to pharmaceutical compositions comprising a physiologically acceptable carrier; an effective amount of a NMPRT inhibitor; and nicotinic acid. The invention also relates to methods for treating a patient diagnosed with or suspected to have a cancer deficient in nicotinic acid pathway.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: July 3, 2012
    Assignee: Gemin X Pharmaceuticals Canada
    Inventors: Anne Roulston, Pierre Beauparlant
  • Compositions and methods for effecting NADlevels using a nicotinamide phosphoribosyl transferase inhibitor
    Patent number: 8173677
    Abstract: The present invention relates to methods for decreasing cellular DNA repair in a patient diagnosed with or suspected to have chronic lymphocytic leukemia (CLL); decreasing cellular NAD+ biosynthesis in a patient diagnosed with or suspected to have CLL; or sensitizing a patient diagnosed with or suspected to have CLL to a DNA damaging therapy. The invention relates to methods for treating a patient diagnosed with or suspected to have CLL.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: May 8, 2012
    Assignee: Gemin X Pharmaceuticals Canada Inc.
    Inventors: Anne Roulston, Pierre Beauparlant
  • COMPOSITIONS AND METHODS FOR EFFECTING NAD+ LEVELS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE INHIBITOR
    Publication number: 20090215823
    Abstract: The present invention relates to methods for decreasing cellular DNA repair in a patient diagnosed with or suspected to have chronic lymphocytic leukemia (CLL); decreasing cellular NAD+ biosynthesis in a patient diagnosed with or suspected to have CLL; or sensitizing a patient diagnosed with or suspected to have CLL to a DNA damaging therapy. The invention relates to methods for treating a patient diagnosed with or suspected to have CLL.
    Type: Application
    Filed: March 25, 2009
    Publication date: August 27, 2009
    Inventors: Anne Roulston, Pierre Beauparlant
  • Compositions and Methods for Effecting NAD+ Levels Using A Nicotinamide Phosphoribosyl Tranferase Inhibitor
    Publication number: 20090162454
    Abstract: The present invention relates to methods for decreasing cellular DNA repair in a target patient; decreasing cellular NAD+ biosynthesis in a target patient; increasing efficiency of radiation therapy in a target patient; modulating nicotinamide phosphoribosyl transferase activity in a patient; or sensitizing a patient to a DNA damaging therapy. The invention relates to methods for treating a patient who received a toxic dose of an nicotinamide phosphoribosyl transferase inhibitor. The invention also relates to pharmaceutical compositions comprising a physiologically acceptable carrier; an effective amount of a NMPRT inhibitor; and nicotinic acid. The invention also relates to methods for treating a patient diagnosed with or suspected to have a cancer deficient in nicotinic acid pathway.
    Type: Application
    Filed: September 25, 2008
    Publication date: June 25, 2009
    Inventors: Anne Roulston, Pierre Beauparlant
  • Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
    Publication number: 20060035945
    Abstract: The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus.
    Type: Application
    Filed: September 13, 2005
    Publication date: February 16, 2006
    Inventors: Giorgio Attardo, Anne Roulston